News Roche's MS drug Ocrevus priced in line with Novartis rival i... Drug likely to cost just under £10,000 per six-monthly injection.
News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
Views & Analysis ‘Listen to your patients’: the best MS care honoured at QuDo... Best healthcare professionals working in multiple sclerosis (MS) honoured QuDoS awards.
News Roche’s MS drug Ocrevus nears European market Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date.<
News Apitope announces IPO to fund MS drug development Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug.
News Bayer gets swift review for Kerendia in type 1 diabetes FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
